Differential Inhibition of Ex-Vivo Tumor Kinase Activity by Vemurafenib in BRAF(V600E) and BRAF Wild-Type Metastatic Malignant Melanoma

BACKGROUND: Treatment of metastatic malignant melanoma patients harboring BRAF(V600E) has improved drastically after the discovery of the BRAF inhibitor, vemurafenib. However, drug resistance is a recurring problem, and prognoses are still very bad for patients harboring BRAF wild-type. Better marke...

Descripción completa

Detalles Bibliográficos
Autores principales: Tahiri, Andliena, Røe, Kathrine, Ree, Anne H., de Wijn, Rik, Risberg, Karianne, Busch, Christian, Lønning, Per E., Kristensen, Vessela, Geisler, Jürgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3758344/
https://www.ncbi.nlm.nih.gov/pubmed/24023633
http://dx.doi.org/10.1371/journal.pone.0072692

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3758344/
https://www.ncbi.nlm.nih.gov/pubmed/24023633
http://dx.doi.org/10.1371/journal.pone.0072692

Ejemplares similares